Periodontal Therapeutics

Periodontal Therapeutics

Global Periodontal Therapeutics Market to Reach US$801.9 Million by 2030

The global market for Periodontal Therapeutics estimated at US$448.9 Million in the year 2023, is expected to reach US$801.9 Million by 2030, growing at a CAGR of 8.6% over the analysis period 2023-2030. Systemic Antibiotics, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$623.3 Million by the end of the analysis period. Growth in the Local Antibiotics segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$117.5 Million While China is Forecast to Grow at 11.6% CAGR

The Periodontal Therapeutics market in the U.S. is estimated at US$117.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$179.2 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR.

Global Periodontal Therapeutics Market - Key Trends & Drivers Summarized

Why Are Periodontal Therapeutics Gaining Prominence as a Crucial Aspect of Dental Health Care?

Periodontal therapeutics are gaining prominence as a crucial aspect of dental health care due to their ability to treat and manage periodontal diseases effectively, which are among the most prevalent oral health issues worldwide. Periodontal diseases, including gingivitis and periodontitis, affect the supporting structures of the teeth, such as the gums, alveolar bone, and periodontal ligament. These conditions, if left untreated, can lead to tooth loss and have been linked to systemic health issues like cardiovascular diseases, diabetes, and respiratory problems. The growing awareness of the importance of oral health and its connection to overall well-being is driving demand for effective periodontal therapeutic solutions that go beyond traditional dental care.

Periodontal therapeutics include a wide range of treatment modalities, such as antimicrobial agents, local drug delivery systems, and host-modulation therapies, designed to reduce bacterial infection, inflammation, and tissue destruction. These therapies are used in conjunction with conventional mechanical treatments like scaling and root planing to provide comprehensive management of periodontal diseases. The ability of these therapeutic agents to target specific pathogens and inflammatory pathways makes them an essential component in the prevention, treatment, and management of periodontal conditions. Additionally, periodontal therapeutics are being increasingly recognized for their role in enhancing the outcomes of periodontal surgeries and regenerative procedures, supporting tissue regeneration and reducing postoperative complications. As awareness of periodontal health continues to rise, the demand for advanced therapeutic options that offer efficacy, convenience, and safety is expected to grow significantly.

How Are Technological Advancements Transforming the Periodontal Therapeutics Market?

Technological advancements are transforming the periodontal therapeutics market by enabling the development of more effective, targeted, and patient-friendly treatment options. One of the most significant innovations in this field is the use of advanced local drug delivery systems (LDDS) that allow for the controlled and sustained release of therapeutic agents directly into periodontal pockets. These systems, which include biodegradable gels, strips, and microspheres, deliver antimicrobial or anti-inflammatory agents at the site of infection, maximizing therapeutic efficacy while minimizing systemic exposure and side effects. For example, chlorhexidine chips, doxycycline gels, and minocycline microspheres are being used to treat localized infections and reduce periodontal pocket depth, improving clinical outcomes.

Another transformative trend is the development of host-modulation therapies that target the host’s immune response to periodontal pathogens. Unlike traditional antimicrobial treatments that focus on eradicating bacteria, host-modulation therapies aim to reduce the destructive inflammatory response associated with periodontitis and promote the healing of periodontal tissues. Agents such as sub-antimicrobial dose doxycycline (SDD), which inhibits matrix metalloproteinases (MMPs) responsible for tissue breakdown, and nonsteroidal anti-inflammatory drugs (NSAIDs), which reduce inflammation, are being explored for their potential to complement conventional periodontal therapies. The integration of biologics, such as growth factors and stem cells, in periodontal treatment is further enhancing the ability to regenerate lost periodontal tissues and improve clinical outcomes.

The use of laser therapy and photodynamic therapy (PDT) is also revolutionizing periodontal treatment by providing minimally invasive options that target pathogens and reduce inflammation with precision. Lasers can be used to debride infected periodontal pockets, promote tissue healing, and achieve hemostasis with minimal discomfort and faster recovery times compared to traditional surgical methods. Photodynamic therapy, which involves the use of a photosensitizing agent activated by light to produce reactive oxygen species that kill bacteria, is being used as an adjunctive treatment to scaling and root planing. These technologies are making periodontal therapies more effective, less invasive, and more acceptable to patients, supporting their widespread adoption.

Additionally, advancements in diagnostic technologies are supporting earlier detection and more personalized management of periodontal diseases. The development of point-of-care diagnostics and salivary biomarkers is enabling dentists to assess periodontal disease activity, predict disease progression, and tailor treatment plans based on individual patient profiles. The use of digital imaging and 3D modeling is also enhancing treatment planning and patient communication, allowing for more precise and predictable outcomes. As these technologies continue to evolve, they are making periodontal therapeutics more targeted, effective, and aligned with the needs of modern dental care.

What Role Do Growing Awareness and Rising Prevalence of Periodontal Diseases Play in Driving the Adoption of Periodontal Therapeutics?

Growing awareness of the impact of periodontal diseases on oral and systemic health, coupled with the rising prevalence of these conditions, is playing a pivotal role in driving the adoption of periodontal therapeutics. Periodontal diseases are among the most common oral health issues globally, affecting millions of people across different age groups and demographics. Factors such as poor oral hygiene, smoking, diabetes, and certain medications can increase the risk of developing periodontal conditions. As the global population ages and the incidence of lifestyle-related diseases such as diabetes continues to rise, the prevalence of periodontal diseases is expected to increase, creating a greater need for effective therapeutic interventions.

Awareness campaigns by dental associations, healthcare organizations, and government bodies are highlighting the importance of maintaining periodontal health and its link to overall health outcomes. Studies have shown that untreated periodontal diseases can contribute to the development or worsening of systemic conditions such as cardiovascular diseases, respiratory infections, adverse pregnancy outcomes, and metabolic disorders. This growing body of evidence is raising public and professional awareness of the need for proactive periodontal care and management. As a result, more patients are seeking treatment for periodontal issues, and dental professionals are increasingly incorporating advanced periodontal therapies into their practice.

The emphasis on early intervention and preventive care is also influencing the demand for periodontal therapeutics. Regular dental check-ups and periodontal screenings allow for the early detection of periodontal diseases, enabling timely intervention before the condition progresses to more severe stages. The availability of minimally invasive therapeutic options, such as local drug delivery systems and laser treatments, is encouraging patients to seek treatment earlier, improving long-term outcomes and reducing the need for more invasive procedures. As awareness of the benefits of periodontal health continues to grow, the adoption of periodontal therapeutics that support early intervention, effective management, and enhanced patient outcomes is expected to rise significantly.

What Factors Are Driving the Growth of the Global Periodontal Therapeutics Market?

The growth in the global periodontal therapeutics market is driven by several factors, including the rising prevalence of periodontal diseases, increasing awareness of oral health’s impact on overall well-being, and the ongoing development of innovative treatment modalities. One of the primary growth drivers is the growing incidence of periodontal diseases, which are associated with factors such as aging, poor oral hygiene, and comorbid conditions like diabetes and cardiovascular disease. As periodontal diseases are a leading cause of tooth loss and have been linked to various systemic health issues, the demand for effective therapeutic interventions that can manage and treat these conditions is increasing. The rising number of geriatric patients, who are more susceptible to periodontal issues, is also contributing to market growth.

The increasing focus on the relationship between oral health and systemic health is another key factor influencing market dynamics. Studies demonstrating the link between periodontal diseases and conditions such as heart disease, stroke, diabetes, and respiratory infections have underscored the importance of maintaining periodontal health as part of overall health management. This has led to a greater emphasis on periodontal disease prevention, early detection, and comprehensive treatment, driving the adoption of advanced therapeutic options that go beyond traditional mechanical treatments. The integration of periodontal care into general healthcare practices is further supporting the growth of the market, as dentists and healthcare providers collaborate to provide holistic care for patients with periodontal conditions.

Ongoing innovations in periodontal treatment modalities are also contributing to the growth of the market. The development of advanced local drug delivery systems, host-modulation therapies, and biologic agents is enhancing the efficacy and outcomes of periodontal treatments. For instance, the use of biodegradable microspheres and strips for sustained drug release is providing targeted therapy with fewer side effects and better patient compliance. The incorporation of growth factors and stem cells in regenerative therapies is enabling the regeneration of lost periodontal tissues, addressing one of the biggest challenges in periodontology. These innovations are expanding the treatment options available to dental professionals and improving the prognosis for patients with periodontal diseases.

Moreover, the increasing investment in research and development (R&D) and the expansion of clinical trials for new periodontal therapies are creating new opportunities for the market. Pharmaceutical companies, dental product manufacturers, and research institutions are collaborating to develop novel therapeutic agents that target the underlying mechanisms of periodontal diseases, such as inflammation and tissue destruction. The growing focus on personalized medicine and precision dentistry is driving the development of therapies that are tailored to individual patient needs and genetic profiles. The use of advanced diagnostics and biomarkers to identify high-risk patients and monitor treatment response is supporting the shift towards more personalized and effective periodontal care.

Additionally, the rising demand for minimally invasive and patient-friendly treatment options is influencing the adoption of advanced periodontal therapeutics. Patients are increasingly seeking treatments that offer reduced pain, shorter recovery times, and minimal disruption to daily life. Minimally invasive options, such as local drug delivery systems, laser therapy, and photodynamic therapy, are gaining popularity as they provide effective treatment with fewer side effects and greater convenience compared to traditional surgical methods. The growing acceptance of these therapies among patients and dental professionals is supporting the expansion of the periodontal therapeutics market.

Furthermore, the impact of the COVID-19 pandemic has highlighted the importance of oral health as part of overall health and immunity. The increased awareness of health and hygiene during the pandemic has led to a greater focus on preventive dental care and the management of chronic conditions such as periodontal diseases. The adoption of telemedicine and remote consultations has also enabled patients to access periodontal care and guidance, supporting the demand for at-home therapeutic products and digital health solutions. As these factors converge, the global periodontal therapeutics market is poised for robust growth, driven by technological advancements, increasing awareness, and the expanding range of treatment options available to address the diverse needs of patients with periodontal conditions.

Select Competitors (Total 18 Featured) -

• 3M ESPE
• Align Technology, Inc.
• Bausch Health Companies Inc.
• DenMat Holdings LLC
• DENTSPLY International, Inc.
• Eli Lilly and Company
• Fibrocell Science, Inc.
• Glidewell Laboratories
• Kaken Pharmaceutical Co., Ltd.
• Mallinckrodt Pharmaceuticals
• Nobel Biocare Holding AG
• OraPharma
• Purdue Pharma LP
• Teva Pharmaceutical Industries Ltd.
• TOLMAR Pharmaceuticals, Inc.
• Ultradent Products, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.